153 related articles for article (PubMed ID: 36610667)
21. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?
Neurohr C; Hoffmann AL; Huppmann P; Herrera VA; Ihle F; Leuschner S; von Wulffen W; Meis T; Baezner C; Leuchte H; Baumgartner R; Zimmermann G; Behr J
Respir Res; 2011 May; 12(1):66. PubMed ID: 21600034
[TBL] [Abstract][Full Text] [Related]
22. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis.
Seyama K; Kumasaka T; Souma S; Sato T; Kurihara M; Mitani K; Tominaga S; Fukuchi Y
Lymphat Res Biol; 2006; 4(3):143-52. PubMed ID: 17034294
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Long-Term Sirolimus Therapy for Asian Patients with Lymphangioleiomyomatosis.
Takada T; Mikami A; Kitamura N; Seyama K; Inoue Y; Nagai K; Suzuki M; Moriyama H; Akasaka K; Tazawa R; Hirai T; Mishima M; Hayashida M; Hirose M; Sugimoto C; Arai T; Hattori N; Watanabe K; Tamada T; Yoshizawa H; Akazawa K; Tanaka T; Yagi K; Young LR; McCormack FX; Nakata K
Ann Am Thorac Soc; 2016 Nov; 13(11):1912-1922. PubMed ID: 27513278
[TBL] [Abstract][Full Text] [Related]
24. Pregnancy in lymphangioleiomyomatosis: clinical and lung function outcomes in two national cohorts.
Taveira-DaSilva AM; Johnson SR; Julien-Williams P; Johnson J; Stylianou M; Moss J
Thorax; 2020 Oct; 75(10):904-907. PubMed ID: 32788260
[TBL] [Abstract][Full Text] [Related]
25. Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.
Yao J; Taveira-DaSilva AM; Jones AM; Julien-Williams P; Stylianou M; Moss J
Am J Respir Crit Care Med; 2014 Dec; 190(11):1273-82. PubMed ID: 25329516
[TBL] [Abstract][Full Text] [Related]
26. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P).
Urban T; Lazor R; Lacronique J; Murris M; Labrune S; Valeyre D; Cordier JF
Medicine (Baltimore); 1999 Sep; 78(5):321-37. PubMed ID: 10499073
[TBL] [Abstract][Full Text] [Related]
27. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
[TBL] [Abstract][Full Text] [Related]
28. Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis.
Hu S; Wu X; Xu W; Tian X; Yang Y; Wang ST; Liu S; Xu X; Xu KF
Orphanet J Rare Dis; 2019 Aug; 14(1):206. PubMed ID: 31429781
[TBL] [Abstract][Full Text] [Related]
29. Evolution of lung pathology in lymphangioleiomyomatosis: associations with disease course and treatment response.
Miller S; Stewart ID; Clements D; Soomro I; Babaei-Jadidi R; Johnson SR
J Pathol Clin Res; 2020 Jul; 6(3):215-226. PubMed ID: 32352655
[TBL] [Abstract][Full Text] [Related]
30. Long-term results of sirolimus treatment in lymphangioleiomyomatosis: a single referral centre experience.
Revilla-López E; Berastegui C; Méndez A; Sáez-Giménez B; Ruiz de Miguel V; López-Meseguer M; Monforte V; Bravo C; Pujana MA; Ramon MA; Gómez-Ollés S; Roman A;
Sci Rep; 2021 May; 11(1):10171. PubMed ID: 33986388
[TBL] [Abstract][Full Text] [Related]
31. The vitamin D binding protein axis modifies disease severity in lymphangioleiomyomatosis.
Miller S; Coveney C; Johnson J; Farmaki AE; Gupta N; Tobin MD; Wain LV; McCormack FX; Boocock DJ; Johnson SR
Eur Respir J; 2018 Nov; 52(5):. PubMed ID: 30093573
[TBL] [Abstract][Full Text] [Related]
32. Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre.
Baldi BG; Samano MN; Campos SV; de Oliveira MR; Junior JEA; Carraro RM; Teixeira RHOB; Minguini IP; Burlina R; Pato EZS; Carvalho CRR; Costa AN
Lung; 2017 Dec; 195(6):699-705. PubMed ID: 28823029
[TBL] [Abstract][Full Text] [Related]
33. Computer grading of lung disease severity in patients with lymphangioleiomyomatosis referred for transplantation.
Taveira-DaSilva AM; Gopalakrishnan V; Yao J; Chen MY; Julien-Williams P; Jones AM; Pacheco-Rodriguez G; Moss J
BMC Pulm Med; 2022 Sep; 22(1):362. PubMed ID: 36153516
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of low-dose Sirolimus in Lymphangioleiomyomatosis.
Yoon HY; Hwang JJ; Kim DS; Song JW
Orphanet J Rare Dis; 2018 Nov; 13(1):204. PubMed ID: 30428897
[TBL] [Abstract][Full Text] [Related]
35. A phase II clinical trial of the Safety Of Simvastatin (SOS) in patients with pulmonary lymphangioleiomyomatosis and with tuberous sclerosis complex.
Krymskaya VP; Courtwright AM; Fleck V; Dorgan D; Kotloff R; McCormack FX; Kreider M
Respir Med; 2020 Mar; 163():105898. PubMed ID: 32125970
[TBL] [Abstract][Full Text] [Related]
36. Safety and Efficacy of Combined Resveratrol and Sirolimus in Lymphangioleiomyomatosis.
Gupta N; Zhang B; Zhou Y; McCormack FX; Ingledue R; Robbins N; Kopras EJ; McMahan S; Singla A; Swigris J; Cole AG; Holz MK
Chest; 2023 May; 163(5):1144-1155. PubMed ID: 36642366
[TBL] [Abstract][Full Text] [Related]
37. Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosis.
Taveira-DaSilva AM; Jones AM; Julien-Williams PA; Stylianou M; Moss J
Chest; 2015 Jan; 147(1):180-187. PubMed ID: 25167325
[TBL] [Abstract][Full Text] [Related]
38. Quantitative CT predicts the severity of physiologic dysfunction in patients with lymphangioleiomyomatosis.
Crausman RS; Lynch DA; Mortenson RL; King TE; Irvin CG; Hale VA; Newell JD
Chest; 1996 Jan; 109(1):131-7. PubMed ID: 8549175
[TBL] [Abstract][Full Text] [Related]
39. Lymphangioleiomyomatosis in patients with tuberous sclerosis: a national centre audit.
Johnson J; Somerfield W; Johnson SR
Orphanet J Rare Dis; 2024 Mar; 19(1):137. PubMed ID: 38532450
[TBL] [Abstract][Full Text] [Related]
40. [Standard technical specifications for methacholine chloride (Methacholine) bronchial challenge test (2023)].
; ;
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Feb; 47(2):101-119. PubMed ID: 38309959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
